pING-HER3 Vaccine for Cancer

Purpose of this Study

We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.

Who Can Participate?

Eligibility

People who have gotten previous treatment with surgery and/or chemotherapy + radiation for one of the following cancers:<ul>
<li>Breast</li>
<li>Colon</li>
<li>Lung</li>
<li>Prostate</li>
<li>Ovarian</li>
<li>Cervical</li>
<li>Endometrial</li>
<li>Gastric (stomach)</li>
<li>Pancreatic</li>
<li>Bladder</li>
<li>Head and neck</li>
<li>Liver</li>
<li>Esophageal</li></ul>
For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.

What is Involved?

If you choose to join this study, you will:<ul>
<li>Get the study vaccine three times over 8 weeks</li>
<li>Have occasional blood draws for 5 years</li>
<li>Have a biopsy to collect tumor tissue, if necessary</li></ul>

Study Details

Full Title

ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH RESECTED MALIGNANCIES

Principal Investigator

Michael
Morse

Protocol Number

PRO00104093

NCT ID

NCT03832855

Phase

I

Enrollment Status

Open to Enrollment